Skip to content
The Nexus
DossierENTITY

phase three trial

Coverage of phase three trial in the Nexus archive.

Earliest in view: Jun 1 · 10:49 UTCMost recent: Jun 1 · 10:49 UTC
Co-mentioned in this coverage
Akesoorganization1ivonescimabtopic1non-small cell lung cancertopic1smokerstopic1US$20 billion markettopic1
Recent coverage
  • HEALTHJun 1 · 10:49 UTCSCMP CHINA
    Akeso lung cancer drug shines in trials, boosting hopes in US$20b market

    Akeso's drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers, potentially expanding its approved uses. Analysts predict it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market, with revised upward target prices.